Lonafarnib, Eiger BioPharmaceuticals’ investigational treatment for progeria and progeroid laminopathies, has lost its accelerated assessment status at the European Medicines Agency. The EU marketing authorization application (MAA) for the oral farnesyltransferase inhibitor will now be reviewed under standard timelines.
The US company attributed the change in review status to the EMA's desire to carry out an inspection and to...